Good
Mostly Aligned
Patient Risk:
Low
Summary
Most core claims about the approved indication for hallucinations and delusions associated with Parkinson’s disease psychosis are consistent with the provided label section 1. However, several claims about dementia-related psychosis in Parkinson’s and other dementia settings are not supported by the provided label text, and the assessment cannot fully confirm scope vs motor symptoms because only a limited excerpt of the label was provided.
Category Scores
Accurate Statements
Nuplazid is approved for hallucinations and delusions related to Parkinson’s disease psychosis.
Section 1 INDICATIONS AND USAGE: indicated for treatment of hallucinations and delusions associated with Parkinson's disease psychosis.
Nuplazid’s approved role tied to Parkinson’s is specifically for Parkinson’s disease psychosis, not for Parkinson’s disease itself.
Section 1 INDICATIONS AND USAGE limits indication to hallucinations and delusions associated with Parkinson's disease psychosis.
Unsupported Statements
Nuplazid is used for hallucinations and delusions associated with dementia-related psychosis in people with Parkinson’s disease.
The provided label excerpt (Section 1) specifies hallucinations and delusions associated with Parkinson’s disease psychosis and does not mention 'dementia-related psychosis' in people with Parkinson’s disease.
Nuplazid is used for hallucinations and delusions associated with dementia-related psychosis in some other dementia settings.
No provided label text supports any indication for 'dementia-related psychosis' in other dementia settings.
Contradictions
Low
AI Statement
Nuplazid (pimavanserin) is not a treatment for Parkinson’s disease symptoms such as tremor, stiffness, or bradykinesia.
Label Reference
Not directly addressed in the provided label excerpt (Section 1 INDICATIONS AND USAGE only specifies hallucinations/delusions associated with Parkinson’s disease psychosis).
Important Omissions
The AI response (claims provided) did not address dosing/administration, contraindications, boxed warnings, warnings/precautions, or monitoring from the label; these cannot be audited because those label sections were not supplied in the prompt.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
No safety-critical contraindiction/warning/dosing statements were made in the provided AI claims; however, multiple aspects of label safety (boxed warnings, contraindications, and dosing safety) were not available for auditing.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Several claims about 'dementia-related psychosis' in Parkinson’s and other dementia settings are not supported by the provided label excerpt.
Suggested Improvement
Limit statements to the provided FDA label indication wording (hallucinations and delusions associated with Parkinson’s disease psychosis) unless additional label sections are provided to support 'dementia-related psychosis' claims.